Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282020 · ClinicalTrials.gov registry record · Phase 3
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 266
- Enrollment target
NCT02282020 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 266 participants.
The verdict
NCT02282020, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 266 participants
- Enrollment target
Study Summary
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.
Interventions
- DRUG Single agent chemotherapy
- DRUG OLAPARIB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2015-02-06 |
| Est. Completion | 2022-07-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02282020
The ClinicalTrials.gov registry entry for NCT02282020 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Single agent chemotherapy is the first listed.
NCT02282020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02282020 about?
NCT02282020 is a clinical study titled "Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments". Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should h...
What is the current status of trial NCT02282020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 266 participants. The study started on 2015-02-06. Estimated completion is 2022-07-19.
What interventions are being tested in trial NCT02282020?
The interventions under investigation include: Single agent chemotherapy (DRUG), OLAPARIB (DRUG).
Who is sponsoring clinical trial NCT02282020?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.